After the Label Changed: Statins and a Pregnancy Being Planned, Not Discovered
A woman with familial hypercholesterolemia planning a pregnancy asks whether to continue her statin through conception, now that the FDA has removed the drug class's pregnancy contraindication — and how much that label change should actually settle for a patient with her specific risk.
Josephine A., a 29-year-old veterinary technician, has been planning this pregnancy for over a year — long enough that she brought a typed list of questions to her preconception visit, most of them about her cats' vaccination schedule crossing over with her own, and one, added almost as an afterthought at the bottom, about the atorvastatin she's been on since her diagnosis with heterozygous familial hypercholesterolemia at nineteen. She'd read online, correctly, that statins used to carry a pregnancy warning, and less correctly, that they still do.
Her untreated LDL, drawn before she ever started therapy, was 265mg/dL; on atorvastatin 20mg it now runs around 130, still above ideal but a substantial improvement she has maintained for a decade without incident. The actual regulatory picture has shifted meaningfully since she first started the drug: in July 2021, the FDA removed the pregnancy contraindication that used to sit on every statin label, concluding after review that the teratogenicity data behind it were weaker and more confounded than the blanket warning had implied, and explicitly noting that in high-risk patients the benefit of continued treatment might outweigh a risk that had never been firmly established in the first place.
What the old label never fully separated out is the difference between a patient taking a statin for routine primary prevention, where stopping for nine months carries little downside, and a patient like Josephine, whose untreated LDL sits well above 250 and whose family history — a father who had his first MI at 43 — suggests a genotype with real vascular consequence if left unmanaged for the better part of a year. What that label change does and doesn't settle for a specific 29-year-old with a specific FH mutation, rather than for statins as a class in the abstract, is the actual question in front of the room today.
In preconception counseling, a warning label that changed
The FDA removed statins' pregnancy contraindication from labeling in 2021, and it's worth being precise about why: the original teratogenicity concern rested on weak, largely retrospective and confounded data, not a confirmed mechanism, and the agency's own review concluded the evidence didn't support an outright contraindication, especially in high-risk patients where the benefit of continued therapy may be substantial. For a patient with genetically confirmed heterozygous familial hypercholesterolemia and an untreated LDL in her range, I would not reflexively stop her statin the moment she starts trying to conceive.
The label change is real and I don't want to undersell it, but 'no longer contraindicated' is a narrower claim than 'proven safe throughout pregnancy,' and I think that distinction matters for how we counsel her. Cholesterol and its downstream products are genuinely required for fetal steroidogenesis and membrane synthesis in a way that's biologically different from most of the drugs we routinely continue through pregnancy — the theoretical concern was never absurd, even if the specific teratogenicity data behind the old contraindication turned out to be weak.
I'd frame this to her as a genuinely individualized decision rather than a settled one now that the label has changed, which is different from either the old default (stop it, no exceptions) or a new default in the other direction (continue it, no discussion).
That's a fair distinction, and I'd draw the line the same way you're drawing it: her heterozygous FH with an untreated LDL of 265 is not the same case as a patient on a statin for routine primary prevention. For her specifically, I would present continuing atorvastatin through conception and into pregnancy as a reasonable, guideline-consistent option pending her own values — not something we default her onto without a real conversation, and not something we reflexively pull the moment a pregnancy test is positive either.
Agreed: present continuing atorvastatin through conception as a reasonable option for Josephine specifically, given her FH severity, framed honestly as an individualized decision rather than either the old reflexive stop or a new reflexive continue. Both physicians wanted her own values in the room, not just the regulatory history, before she decided.
Not agreed: whether to recommend continuing through the full pregnancy or switching to colesevelam once conception is confirmed. The maternal-fetal medicine physician would lean toward continuing the statin given her FH severity and the still-limited alternatives; the pharmacologist would want that decision revisited case by case as more of the post-2021 real-world safety data accumulate, rather than settled today for the entire pregnancy in advance. Josephine was told plainly that this second decision remains open and will be revisited once she conceives.